PNC Financial Services Group’s PMV Pharmaceuticals PMVP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$91K Sell
67,938
-354
-0.5% -$454 ﹤0.01% 2997
2026
Q1
$84.7K Sell
68,292
-4,919
-7% -$6.26K ﹤0.01% 2926
2025
Q4
$91.5K Buy
73,211
+2,205
+3% +$2.95K ﹤0.01% 2853
2025
Q3
$99.4K Buy
71,006
+10,186
+17% +$14.1K ﹤0.01% 2811
2025
Q2
$64.5K Sell
60,820
-1,314
-2% -$1.29K ﹤0.01% 2972
2025
Q1
$67.7K Sell
62,134
-6,979
-10% -$9.47K ﹤0.01% 2917
2024
Q4
$104K Sell
69,113
-116
-0.2% -$184 ﹤0.01% 2651
2024
Q3
$103K Buy
69,229
+25,983
+60% +$40.1K ﹤0.01% 2654
2024
Q2
$70.1K Buy
43,246
+43,220
+166,231% +$77.9K ﹤0.01% 2848
2024
Q1
$44 Hold
26
– – ﹤0.01% 4668
2023
Q4
$81 Sell
26
-961
-97% -$2.54K ﹤0.01% 4530
2023
Q3
$6.06K Hold
987
– – ﹤0.01% 3936
2023
Q2
$6.18K Hold
987
– – ﹤0.01% 4053
2023
Q1
$4.71K Buy
+987
New +$6.95K ﹤0.01% 4058

Other funds holding PMVP

PNC Financial Services Group's PMVP Position: Q2 2026 in Review

PNC Financial Services Group reduced its PMV Pharmaceuticals (PMVP) stake by 0.52% in Q2 2026, selling an estimated $454 and leaving 67,938 shares worth $91K. The position accounts for ﹤0.01% of the portfolio, ranked #2997.

PNC Financial Services Group first reported a position in PMVP in Q1 2023 and has held it in 14 quarters since. The position peaked at $104K in Q4 2024. 64 funds tracked by Wall St. Rank hold PMVP as of Q2 2026.

  • PNC Financial Services Group held 67,938 shares of PMV Pharmaceuticals worth $91K as of Q2 2026.
  • PNC Financial Services Group sold 354 PMV Pharmaceuticals shares in Q2 2026, an estimated $454.
  • PMV Pharmaceuticals made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #2997 holding.
  • PNC Financial Services Group first reported a position in PMV Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • PNC Financial Services Group's PMV Pharmaceuticals position peaked at $104K in Q4 2024.
  • 64 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.